KindlyMD (NASDAQ:NAKA) Stock Price Target Lowered at B. Riley Financial

KindlyMD (NASDAQ:NAKA – Get Free Report) had its target price decreased by research analysts at B. Riley Financial from $13.00 to $10.00 in a report issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. B. Riley Financial‘s price target points to a potential upside of 100.00% from the stock’s current price.

A number of other research firms have also weighed in on NAKA. Wall Street Zen raised KindlyMD from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KindlyMD in a research note on Wednesday, November 4th. Finally, TD Cowen raised their target price on KindlyMD from $1.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

Check Out Our Latest Analysis on NAKA

KindlyMD Stock Performance

Shares of KindlyMD stock opened at $5.00 on Monday. The stock has a market cap of $91.73 million, a P/E ratio of -0.33 and a beta of 16.03. The stock’s 50 day simple moving average is $7.87 and its 200-day simple moving average is $7.52. KindlyMD has a 1-year low of $3.33 and a 1-year high of $25.22. The company has a debt-to-equity ratio of 0.18, a current ratio of 0.23 and a quick ratio of 0.23.

KindlyMD (NASDAQ:NAKA – Get Free Report) last posted its quarterly earnings results on Friday, November 13th. The company reported $4.07 EPS for the quarter, beating the consensus estimate of ($0.49) by $4.56. KindlyMD had a negative return on equity of 73.53% and a negative net margin of 1,067.93%. The firm had revenue of ($1.93) million during the quarter. Analysts predict that KindlyMD will post -12.94 EPS for the current fiscal year.

Insider Buying and Selling at KindlyMD

In other KindlyMD news, CEO David F. Bailey acquired 32,134 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was purchased at an average cost of $5.59 per share, with a total value of $179,629.06. Following the transaction, the chief executive officer owned 32,134 shares of the company’s stock, valued at $179,629.06. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last three months, insiders acquired 41,904 shares of company stock worth $235,231. Corporate insiders own 24.08% of the company’s stock.

About KindlyMD

(Get Free Report)

KindlyMD is a Utah-based healthcare company that provides outpatient medical services, with a focus on integrated care. Its offerings include primary care, behavioral health and treatment for substance use disorders, along with care coordination intended to connect patients with appropriate services. The company serves patients through clinics in Utah and has emphasized care for people with complex or ongoing health needs. KindlyMD combined with Nakamoto Holdings in 2025; the resulting company trades on Nasdaq under the symbol NAKA.

Further Reading

Receive News & Ratings for KindlyMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KindlyMD and related companies with MarketBeat.com's FREE daily email newsletter.